앨라배마의 과체중 임상 시험
과체중 관련 연구 32개가 앨라배마 내 여러 지역에서 참여자를 모집하고 있습니다.
앨라배마의 도시
공식 연구 텍스트(영어)
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
- AMR Clinical - Mobile, Mobile
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT07685808Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Cahaba Research - Pelham /ID# 282381, Pelham
피험자 모집 중2상
18세 ~ 75세 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT07752979A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Use a Breathing Machine (PAP) (VESPER-OSA 1)
- Cullman Clinical Trials, Cullman
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT07823608Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- University of Alabama - Birmingham, Birmingham
피험자 모집 중2상
18세 ~ 75세 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07837973A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Pinnacle Research Group, LLC, Anniston
- Central Research Associates, Birmingham
- Cahaba Research - Pelham, Pelham
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07794579AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Pinnacle Research Group LLC, Anniston
- Univ of Alabama Birmingham, Birmingham
- Chambliss Clinical Trials LLC, Montgomery
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07720271Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Digestive Health Specialists, Dothan
피험자 모집 중3상
18세 ~ 70세 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT06937099Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Digestive Health Specialists, Dothan
피험자 모집 중3상
18세 ~ 70세 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT06937086A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
- Birmingham Clinical Research, Birmingham
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07392190A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- Cullman Clinical Trials, Cullman
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07369011A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Fairhope
- Research Site, Huntsville
- Research Site, Mobile
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07784270Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- AMR Clinical, Mobile
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07353931A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- MFA Clinical Research, Tuscaloosa
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07321886Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Alliance For Multispecialty Research - Daphne, Daphne
- Eastern Shore Research Institute, Fairhope
- Heart Center Research LLC, Huntsville
- 외 2개
피험자 모집 중3상
45세 ~ 99세 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
- Birmingham Clinical Research, Birmingham
- Cullman Clinical Trials, Cullman
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT07282600A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Birmingham
- AURORA-1 Clinical Site, Huntsville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 16. 업데이트됨 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Birmingham
- AURORA-2 Clinical Site, Huntsville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 16. 업데이트됨 · NCT07743450A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Lakeview Clinical Research, Guntersville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT07351058A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Pinnacle Research Group, Anniston
- Alabama Clinical Therapeutics, Birmingham
- University of Alabama at Birmingham, Birmingham
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Birmingham
피험자 모집 중3상건강한 지원자 환영
18세 ~ 79세 · 모든 성별 · 2026. 9. 11. 업데이트됨 · NCT07654374Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
- Uni of Alabama at Birmingham, Birmingham
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 9. 업데이트됨 · NCT07770841AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
- Univ of Alabama Birmingham, Birmingham
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 4. 업데이트됨 · NCT07533175Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Anniston
- Kailera Clinical Site, Birmingham
- Kailera Clinical Site, Cullman
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT07284875Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Cullman
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Pinnacle Research Group LLC, Anniston
- Alliance For Multispecialty Research - Daphne, Daphne
- Alliance for Multispecialty Research Mobile, Mobile
피험자 모집 중3상
18세 ~ 99세 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT07684235Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Cahaba Research, Inc., Pelham
피험자 모집 중3상
18세 ~ 99세 · 모든 성별 · 2026. 8. 27. 업데이트됨 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Dothan
- Research Site, Huntsville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT07784725Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Birmingham
- ACCOMPLISH-1 Research Site, Birmingham
피험자 모집 중3상
18세 ~ 79세 · 모든 성별 · 2026. 8. 10. 업데이트됨 · NCT07654361Time-restricted Eating for Postpartum Weight Loss
- University of Alabama at Birmingham, Birmingham
피험자 모집 중
18세 이상 · 여성 · 2026. 6. 29. 업데이트됨 · NCT06491537Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
- University of Alabama at Birmingham, Birmingham
피험자 모집 중
18세 ~ 45세 · 여성 · 2026. 6. 24. 업데이트됨 · NCT05124808FELLAShip to Better Health
- The Worship Center Cristian Church, Birmingham
피험자 모집 중
18세 이상 · 남성 · 2026. 1. 22. 업데이트됨 · NCT07220213International Weight Control Registry
- University of Alabama at Birmingham, Birmingham
피험자 모집 중관찰 연구건강한 지원자 환영
18세 이상 · 모든 성별 · 2024. 9. 19. 업데이트됨 · NCT04907396ClinicalTrials.gov 출처, 2026. 9. 30. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.